UBS’s Cytokinetics CYTK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2014
Q3
$1K Sell
300
-1,800
-86% -$7.56K ﹤0.01% 10141
2014
Q2
$10K Sell
2,100
-21,300
-91% -$130K ﹤0.01% 8868
2014
Q1
$222K Buy
+23,400
New +$212K ﹤0.01% 5071
2013
Q4
Sell
-1,300
Closed -$10K 10450
2013
Q3
$10K Buy
+1,300
New +$13.9K ﹤0.01% 8797

Other funds holding CYTK

UBS's CYTK Position: Q3 2014 in Review

UBS increased its Cytokinetics (CYTK) stake by 186% in Q3 2014, buying an estimated $23.4K and bringing the position to 8,556 shares worth $30K. The position accounts for ﹤0.01% of the portfolio, ranked #7464.

UBS first reported a position in CYTK in Q3 2013 and has held it in 5 quarters since. The position peaked at $64K in Q1 2014. 85 funds tracked by Wall St. Rank hold CYTK as of Q3 2014.

  • UBS held 8,556 shares of Cytokinetics worth $30K as of Q3 2014.
  • UBS bought 5,562 Cytokinetics shares in Q3 2014, an estimated $23.4K.
  • Cytokinetics made up ﹤0.01% of UBS's portfolio in Q3 2014, its #7464 holding.
  • UBS first reported a position in Cytokinetics in Q3 2013 and has held it in 5 quarters since.
  • UBS's Cytokinetics position peaked at $64K in Q1 2014.
  • 85 funds tracked by Wall St. Rank held Cytokinetics as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.